Legacie DevelopmentsAvailable
The Gateway
Pumpfields, Liverpool
0%
projected NET rental return
Prices from £354,950
- 6% projected NET rental return
- Completing Q1 2027
- Garden Spa, sky lounge and skybridge floors
Q1 2027View Details
LDLegacie Developments
Developer partner
Legacie Developments
Liverpool & Greater Manchester
North West developer building large residential towers with hotel-grade amenity, currently delivering Liverpool's biggest residential scheme under construction.
2014
Founded
Liverpool & Greater Manchester
Core markets
Why we work with them
Legacie designs, builds and manages its own schemes rather than contracting the work out. That vertical structure is unusual at this scale and it is the main reason we were willing to represent their stock.
The Gateway in Pumpfields comprises four towers and 656 homes. Its sister scheme, SoapWorks, adds a further 381 apartments on the adjacent plot, while West One brings investment apartments to Salford minutes from MediaCityUK.
We assess Legacie on programme discipline and on amenity that a tenant will actually pay for. The Garden Spa and skybridge floors at The Gateway are not decoration; they are the reason the building should hold a rental premium against nearby stock.
On Legacie Developments schemes, 36 Partners acts as sales agent for the developer. Our assessment process is set out in full on our due diligence page.
Available now
Legacie Developments stock we represent
Legacie DevelopmentsAvailable
West One
Salford, Greater Manchester
Rental figures available on enquiry
Prices from £334,950
- Availability and pricing available on enquiry
- Eco-led apartments near MediaCityUK
- Minutes from MediaCityUK and Salford Quays
Off-plan — date to be confirmedView Details
Legacie DevelopmentsAvailable
SoapWorks
Pumpfields, Liverpool
Rental figures available on enquiry
Prices from £329,950
- Current availability and pricing available on enquiry
- Apartments in Liverpool's Pumpfields district
- Spa, cinema, gym and rooftop terraces
Off-plan — date to be confirmedView Details
All yield and growth figures are projected or indicative.